<DOC>
	<DOCNO>NCT00258466</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray type radiation kill tumor cell . Giving radiation therapy different way may kill tumor cell . It yet know type radiation therapy effective treat prostate cancer . PURPOSE : This randomized phase III trial study different type radiation therapy compare well work treat patient stage I , stage II , stage III prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Stage I , Stage II , Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy neutron photon radiotherapy v hypofractionated intensity modulate radiation , term low frequency chronic complication rate ( chronic toxicity disease-free survival ) , patient favorable intermediate prognosis , stage I-III adenocarcinoma prostate . OUTLINE : This randomize , multicenter study . Patients stratify accord stage disease ( T1 vs T2 v T3 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo neutron radiotherapy 15-45 minute 5 day week 2 week follow photon radiotherapy 15-45 minute 5 day week 5 week . - Arm II : Patients undergo photon radiotherapy 15-45 minute 5 day week 5 week follow hypofractionated photon irradiation 15-45 minute 5 day week 2 week . After completion study treatment , patient follow periodically 5 year yearly thereafter . PROJECTED ACCRUAL : A total 300 patient ( 150 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Stage IIII disease ( T1T3 , N0 , M0 ) No clinical radiographic evidence metastasis If prostatespecific antigen ( PSA ) ≥ 10.0 ng/mL Gleason score 7 , radioisotope bone scan must show evidence metastasis No evidence lymphatic visceral metastasis abdomen pelvis CT scan MRI PSA ≤ 20 ng/mL Gleason score ≤ 7 ( stage T3 , score must &lt; 7 ) PATIENT CHARACTERISTICS : Performance status Not specify Life expectancy More 10 year Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No malignancy within past 5 year except basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Endocrine therapy Prior hormonal therapy allow provide initiated 2 month ago , may include follow : Luteinizing hormonereleasing hormone agonist ( e.g. , goserelin , leuprolide ) Antiandrogens ( e.g. , flutamide , bicalutamide ) Radiotherapy No prior pelvic irradiation Surgery No prior radical prostatectomy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>